Background: We describe changes in prostate cancer incidence, survival and mortality and the resulting impact in
introduction
Starting from the late 1980s, opportunistic screening for prostate cancer among asymptomatic men by means of prostate-specific antigen (PSA) testing [1] [2] [3] caused rapid rises in prostate cancer incidence and survival [4] [5] [6] [7] in many Western countries, and by 2008, prostate cancer was estimated to have become the most common malignancy in men in Europe, as well as in North and South America [8] . Evidence from European Randomized Study of Screening for Prostate Cancer (ERSPC) [9] suggested the possibility of reducing prostate cancer mortality through PSA testing, and the better than overall performance of the intervention in a subpopulation of that trial [10] suggests the possibility of substantial geographic variation in the performance of the intervention.
Treatment triggered by PSA testing can cause nonnegligible harm through overdiagnosis [11, 12] , overtreatment [13] and side-effects that can reduce quality of life [14, 15] . PSA testing trial results convincingly indicate no mortality benefit within the first 10 years after screening [9, 12] , and the potentially low effectiveness of PSA testing in the population-based setting [16, 17] additionally increase the difficulty of weighing the harms and benefits associated with PSA testing.
The more than a decade long utilization of PSA testing in the population enables the comparative assessment of the population-level effects of the intervention. A recent analysis addressed overall prostate cancer mortality trends in Europe [18] . We provide a detailed international epidemiological comparison of age-specific incidence, survival and mortality between the beginning of the PSA era, defined as the calendar period of [1985] [1986] [1987] [1988] [1989] in the United States and 1990-1994 in Europe and the early 21st century. Additionally, we attempt to quantify and compare the absolute impact of incidence and mortality changes in terms of additional diagnoses and avoided deaths and examine population life expectancies.
materials and methods data sources
Cancer incidence data came from 12 long-standing population-based cancer registries participating in the European Network for Indicators of Cancer (EUNICE) Survival Cooperation, the NORDCAN database [19] , the Surveillance, Epidemiology and End Results (SEER) Cancer Query Systems (CANQUES) for the United States and the International Agency for Research on Cancer (IARC) (for years up to 1997) [20] . National-level age-specific prostate cancer mortality data were obtained from the World Health Organization (WHO) mortality database [21] , along with additional regional data from the cancer registries.
survival analysis
For European regions, the database of EUNICE Survival Cooperation was used; data preparation, inclusion criteria for survival analysis and population life tables used to calculate relative survival estimates have been described in detail elsewhere [22] . Briefly, this analysis includes men aged ‡40 diagnosed with malignant tumors of the prostate [International Classification of Diseases (ICD)-10 code C61] between 1985 and 2004, excluding diagnoses confirmed by autopsy or death certificate only. For the United States, the public use database of the SEER Program was used. White male prostate cancer patients from the SEER 9 registries were selected using the same criteria as for European patients. Life tables for USA whites, obtained from the US National Center for Health Statistics, for the years 1990, 2000 and 2004 were used to cover the periods of 1990-1995, 1996-2002 and 2003-2004, respectively .
Five-year relative survival estimates were calculated for the age groups of 40-64, 65-74 and 75+, for the periods 1990-1994, 1995-1999, and 2000-2004 . Relative survival estimates were derived as a ratio of the absolute survival of the cancer patients divided by the expected survival of an agematched group of the underlying male general population [23] . Expected survival estimates were derived using the Ederer II method [24] . Life expectancy was calculated on the basis of the population-specific life tables.
We used a saturated Poisson regression model equivalent to period analysis to derive survival estimates [25] . To obtain a test for trend, the above model was extended: the logarithm of the excess number of deaths was modeled as a function of calendar period and year of follow-up, with the logarithm of the person-years (p.y.) at risk as offset [26] . For registries with incidence data up to 2003, but follow-up data through 2004, hybrid analysis was used to take advantage of mortality follow-up data that were more up to date than incidence data [27] . Survival calculations were carried out with the SAS statistical software package using adapted versions of previously described SAS macros [28] .
age adjustment of incidence and mortality data and calculation of changes in the numbers of surplus diagnoses and reductions in deaths of prostate cancer in the PSA era Truncated (ages 40+) age-specific incidence and mortality data adjusted to the World Standard Population (within the age group) were available from the IARC/WHO databases [20, 21] . Cancer registry data were age adjusted to the World Standard [29] . Net differences between incidence/mortality rates at the beginning of the PSA era (1985) (1986) (1987) (1988) (1989) in the United States and 1990-1994 in Europe) and 2002-2006 were calculated, and these were used to calculate age-specific change in the yearly number of diagnoses and number of men dying of prostate cancer, based on a hypothetical underlying population of 1 million men with the age distribution of the 2000 USA male population (equivalent to 300 000, 60 000 and 44 000 men in the age groups 40-64, 65-74 and 75, respectively) [30] . Overall ratios of net standardized change in incidence and mortality were calculated to quantify the absolute effect of incidence and mortality changes in terms of additional diagnoses and avoided deaths in the PSA era.
results Table 1 provides case numbers and median age in each participating cancer registry in 1990-1994, 1995-1999 and 2000-2004 . Overall, 401 162 prostate cancers were included in the analysis. Large increases in the numbers of cases in all registries were accompanied by, except in Estonia and Lithuania, a decrease in the median age at diagnosis of between 1 and 5 years, with particularly strong changes in Geneva (from 73 to 68), Finland (from 74 to 70), Norway (from 75 to 72) and in the United States (from 71 to 68). Table 2 presents age-specific results of the survival analysis. With the exception of the oldest age group in Slovenia and Geneva, the 5-year relative survival of patients has increased (Table 3) rose strongly with age, with the oldest age group having a 4-11 times higher agespecific incidence than the youngest in [2002] [2003] [2004] [2005] [2006] . With the exception of the United States, incidence was always highest in the oldest age group. Among 40-to 64-year-olds, incidence was lower in Central and Southern Europe as well as in Scotland and Eindhoven (rates between 40 and 93 per 100 000 p.y.) than in Northern Europe, Saarland and Geneva (rates between 106 and 146 per 100 000 p.y.). Incidence in the United States was $30% higher in this age group than the highest incidence in Europe. In the age group 65-74, incidence in Cracow was markedly lower (264 per 100 000 p.y.) than in Tuscany, Slovenia, Scotland and Estonia (470-550 per 100 000 p.y.); rates were between 640 and 700 per 100 000 p.y. in Turin, Eindhoven and Saarland, and highest in Geneva, Lithuania, Norway and Finland (760-870 per 100 000 p.y.). Again, incidence in the United States, at $920 per 100 000 p.y., was highest. In the oldest age group, patterns were more uniform: except the much lower incidence in Cracow than elsewhere, rates varied between $670-815 per 100 000 p.y. in all registries except Lithuania, Norway and Finland, where rates exceeded the 1000 per 100 000 p.y. mark and were higher than the rate seen in the United States.
Rises in the incidence between the beginning of the PSA era and 2002-2006 had, except for Estonia, a similar pattern in Europe: the strongest rise, in percentage, was seen in the youngest age group while changes were smallest in the oldest age group. In Europe, incidence increased in all registries in the two youngest age groups; in contrast, essentially unchanged incidence was seen in the oldest age group in Eindhoven, Scotland, Norway and Saarland, and incidence decreased by 10% in Geneva. In the United States, incidence nearly tripled in the age group 40-64, increased by 44% in the age group 65-74, but decreased by 27% in age group 75+.
For mortality, age-specific rates were between 36 and 80 times higher in the oldest age group than in the youngest in 2002-2006. However, the absolute variation between registries was small: rates were between 4 and 13 per 100 000 p.y. in the youngest age group and between 54 and 139 per 100 000 p.y. and 319 and 619 per 100 000 p.y. in the age groups 65-74 and 75+, respectively. Mortality rose in all age groups in Cracow, Estonia, Lithuania and Slovenia, remained largely stable in Scotland, decreased in Tuscany (Italy) in the two youngest age groups by $20%, and decreased by between 5% and 32% in all three age groups in the remaining registries. In the United States, rates declined by 23%-38%. Table 3 also shows the age-specific change in the numbers of men diagnosed and dying of prostate cancer in 1 year (based on 1 million men with the USA age structure as underlying population) by age group and overall. In the age group 40-64, the yearly number of additional diagnosis was between 82 and 354 while changes in the yearly number of men dying of prostate cancer did not exceed 8. In the age group 65-74, numbers of additional diagnoses ranged between 85 and 349 while the change in the number of deaths ranged between +21 and 226. In the oldest age group, corresponding ranges for additional diagnoses were 2133 and +301, and +106 and 289 for deaths. Reductions in the number of death exceeded the number of additional diagnosis in Saarland and Eindhoven, they were approximately equal in Norway, and declines in additional diagnosis were accompanied by even stronger [31] . Table 3 . Changes in truncated (ages 40+) age-adjusted age-specific prostate cancer incidence and mortality rates, resulting rise or decline in the annual numbers of diagnoses and deaths, and the ratio of these, by age group and participating registry e Ratio of surplus diagnosis over mortality decline; negative ratios indicate no mortality decline or declines in both incidence and mortality. In the age group 65-74, a peak and subsequent decline in incidence has already manifested in Saarland and the United States, and may be under way in Finland and Geneva; incidence may be stabilizing in several other populations. In the oldest age group, stable or even slightly declining incidence is seen since the mid/late 1990s in Turin, Eindhoven, Scotland, Finland, Norway, Geneva, and Saarland, while the strongest decline is found in the United States. These incidence declines were uniformly accompanied by declines in mortality as well. In Table 4 , life expectancies of men in the populations included in our analysis are shown. Both overall and conditional life expectancy varied considerably among the populations, with the exact age at which cumulative 10-year life expectancy became <50% varying between 68 and 76 years.
discussion
The PSA era brought about, particularly among patients <75 years of age, strong rises in prostate cancer incidence and survival in both Europe and the United States. PSA utilization spread much quicker in the United States (the rise in incidence was similar to that in Lithuania in 2006, the starting year of the national PSAbased prostate cancer early detection program [31] in that country), and both incidence (with very few exceptions) and survival (uniformly) remain higher in the United States than in Europe. The impressive rises in relative survival are clearly overwhelmingly explained by lead-time and overdiagnosis effects, which strongly compromise the epidemiological interpretability of the changes. Relative declines in mortality were larger and more consistent in the United States compared with European areas. In contrast to other populations, mortality rises were seen in Eastern European populations, and it was argued that this may be an indication of increased risk [18] . Our results (Table 3, Figure 1 ) indicate that in all of these four countries, mortality rises affect the oldest age group far stronger than younger ones. It is difficult to explain the geographic disparity and the disproportionate increase by age. Possible explanations include differential degrees of death misattribution by country, age and time period [32] .
Relative (and sometimes even absolute) incidence rises were largest in the age groups of 40-64 and 65-74, the absolute mortality effect was by far weakest in the age group 40-64 and strongest among patients aged 75+. Everywhere, the number of additional diagnosis in the age group 40-64 alone exceeded, often many times over, the total reduction in the numbers of deaths over the entire age range, as achieved by mortality reductions up to [2002] [2003] [2004] [2005] [2006] . The large variation in overall additional diagnoses versus reductions in prostate cancer mortality indicates considerable geographic differences in the overall effect of disease measure changes by 2006. For many European populations, ratios are considerably less favorable than for the Unites States. The use of age-adjusted incidence and mortality rates mean that the effect of population aging is completely removed from the trends in our analyses.
Unfavorable ratio of surplus incidence over reduction in mortality through PSA testing was found before in the European trial of PSA testing [9] , as well as in population-based analysis [13] . On the population level, beside PSA utilization, other factors may have influenced incidence and mortality. Some natural rise in incidence may have occurred in the pre-PSA era already [33] , making underlying incidence rates higher even in the absence of PSA testing. However, early detection, e.g. through transurethral resection of the prostate (TURP) for benign prostatic disease, was shown to explain most of the increase in incidence seen in the United States between 1973 and 1986 [34] . Comparable TURP trends, though with a smaller explanatory power, were reported from Europe also [35] . Data from clinical trials suggest that PSA testing is unlikely to produce a mortality benefit within the first 10 years after testing [9, 10] . Consequently, it is probably only after 2002 that a part of mortality decline may be due to PSA testing in the United States (where testing peaked in 1992), while in Europe, where utilization was lower in the 1990s, any larger scale effect will probably manifest in even later years. With mortality declines in the two older age groups often ongoing since the early or mid 1990s (Figure 1 ), other factors, rather than PSA testing, are probably responsible for most of the mortality decline.
Clinical progress with neoadjuvant and adjuvant hormonal therapy, which improves disease-specific survival and sometimes also overall survival [36] , may have contributed to lower mortality rates. Furthermore, the long-term use of aspirin and other nonsteroidal anti-inflammatory drugs, reducing the risk of prostate cancer [37] [38] [39] , as well as advancement of diagnosis to younger age groups may have contributed to incidence declines seen in the oldest age group since the mid/late 1990s. On the other hand, for mortality, statins, increasingly utilized since the late 1990s [40] , that have been suggested to reduce the risk of advanced prostate cancer [41, 42] may also have played a role. The share of PSA testing in incidence rises is probably very substantial; its effect on mortality reduction up to 2006 is probably partial, suggesting that a worse total balance than implied by the calculated ratios.
Since 2008, the US Preventive Task Force has recommended against PSA testing in men >75 years of age, as with <10 years of life expectancy, any benefit is unlikely [43] . Data indicate that a substantial proportion of men are being tested even if the available evidence clearly indicates that they cannot obtain a benefit [44] [45] [46] [47] . For many European populations, lower life expectancy suggests that PSA testing should often stop already $70 years of age. Shared and informed decision making is therefore essential to determine patient preferences and the best course of action before and after testing [48] . In practice, this recommendation often remains unfulfilled [49] to which lack of understanding and overestimation of screening benefits in the general population [50] certainly contributes. As guidelines for shared decision making exist [51, 52] , implementing this approach should have a very high priority.
Several limitations of this study require careful consideration. A considerable proportion of men dying within a given year from prostate cancer (and so contributing to mortality) have been diagnosed during preceding years, and this, as well as misclassification [53] turn mortality into an unspecific measure. Furthermore, due to the long lead time associated with a PSA-related diagnosis and the fact that prostate cancer is often a slowly progressing disease, a long time might be necessary until progress against cancer translates into a mortality decline on the population level, and the latter may even occur in a different age group than the diagnosis. It cannot be excluded that PSA testing associated mortality declines will occur in the future-the more time this should take, the more likely it is that such decline will affect older ages. More detailed data, particularly uniformly assessed stage, could have enabled deeper insight into reasons for survival differences.
In summary, highly elevated incidence, large geographical variation in the dynamics of prostate cancer, considerable international differences in life expectancy, the need for tools that enable informed and shared decision making, as well as evidence that testing continues to be widespread in older populations that are likely to be only harmed suggest that the complex issue of prostate cancer screening may be best addressed at the policy level. 
